Amgen (NASDAQ: AMGN) today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013. Romosozumab data include results from the Phase 2…
Source: Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting
Saturday, October 5, 2013
Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment